Clinical Trial Design, Endpoints, and Regulatory Requirements.

about

Clinical Trial Design, Endpoints, and Regulatory Requirements.

Item

http://www.wikidata.org/entity/Q47632649

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Clinical Trial Design, Endpoints, and Regulatory Requirements.

@en

Clinical Trial Design, Endpoints, and Regulatory Requirements.

@nl

type

Item

label

Clinical Trial Design, Endpoints, and Regulatory Requirements.

@en

Clinical Trial Design, Endpoints, and Regulatory Requirements.

@nl

prefLabel

Clinical Trial Design, Endpoints, and Regulatory Requirements.

@en

Clinical Trial Design, Endpoints, and Regulatory Requirements.

@nl

P1476

Clinical Trial Design, Endpoints, and Regulatory Requirements.

@en

P2093

Giuseppe M C Rosano

http://www.w3.org/2001/XMLSchema#string

P2860

Is hospital admission for heart failure really necessary?: the role of the emergency department and observation unit in preventing hospitalization and rehospitalization

Developing therapies for heart failure with preserved ejection fraction: current state and future directions

Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.

Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries.

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contrib

The disconnect between phase II and phase III trials of drugs for heart failure.

Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document.

Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics', clinicians', industry's, regulators', and payers' perspectives.

Steps forward in regulatory pathways for acute and chronic heart failure.

Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency.

P304

67-78

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/164_2016_75

http://www.w3.org/2001/XMLSchema#string

P478

243

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27787710

http://www.w3.org/2001/XMLSchema#string